Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuroblastoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Experimental group?combined induction chemotherapy with arsenic trioxide Control group?conventional induction chemotherapy without arsenic trioxideMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 14 years
- Gender
- Both males and females
Description
Patients are randomly divided into experimental group and control group. Experimental group receive arsenic trioxide combined with induction chemotherapy while control group receive conventional induction chemotherapy alone. The 3 year overall survival rate (OS) and progression free survival (PFS), ...
Patients are randomly divided into experimental group and control group. Experimental group receive arsenic trioxide combined with induction chemotherapy while control group receive conventional induction chemotherapy alone. The 3 year overall survival rate (OS) and progression free survival (PFS), as well as incidence of adverse events, will be compared between two groups. Patients are followed every 3 months in the first year, every 6 months in the second year, and then annually thereafter.
Tracking Information
- NCT #
- NCT03503864
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon